1. 09.02 Bispecific antibodies enable synthetic agonistic receptor T cell therapy in melanoma. (21st September 2022) Authors: Benmebarek, M; Märkl, F; Keyl, J; Cadilha, B; Geiger, M; Karches, C; Obeck, H; Schwerdtfeger, M; Briukhovetska, D; Jobst, J; Müller, PJ; Seifert, M; Grünmeier, R; Thomas, M; Marr, C; Levesque, M; Heppt, M; Endres, S; Klein, C; Kobold, S Journal: Journal for immunotherapy of cancer Issue: Volume 10(2022)Supplement 1 Page Start: A4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P06.01 Bispecific antibody-driven synthetic agonistic receptor – transduced T cells mediate specific and conditional therapy in melanoma cancer models. (1st October 2020) Authors: Benmebarek, M; Keyl, J; Märkl, F; Geiger, M; Karches, C; Rausch, S; Gottschlich, A; Öner, A; Feinendegen, M; Dörr, J; Cadilha, B; Endres, S; Klein, C; Kobold, S Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗